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LETTERS TO THE EDITOR
Heterogeneity of Patients With Coronary
Artery Disease and Distress and the Need
to Identify Relevant Subtypes
D rs Frasure-Smith and Lespe´rance
1 showed that
in patients with stable coronary artery disease
(CAD), major depressive disorder (MDD) and
generalized anxiety disorder (GAD) showsubstantial over-
lap and both are associated with prospective major ad-
verse coronary events. The self-report screening instru-
ments for depression (BeckDepression Inventory Second
Edition) and anxiety (Hospital Anxiety and Depression
Scale anxiety subscale) were strongly correlated and their
predictive values for the diagnosis of MDD were virtu-
ally the same. Drs Frasure-Smith and Lespe´rance sug-
gest that a distress disorder under which both depres-
sion and anxiety would fall would be amore appropriate
diagnostic category to be included in DSM-V. In general
psychiatry, the suggestion of combining MDD and GAD
has many advocates but also many opponents, fueled
by differences between patients with MDD and GAD in
magnetic resonance imaging patterns and response to
benzodiazepines.
In patients with CAD, 3 other distinctions of distress
may be more relevant, which Drs Frasure-Smith and
Lespe´rance unfortunately failed to discuss. First of all,
the increased cardiac risk in post–myocardial infarction
(MI) depression appears to be restricted to first-ever (in-
cident) depressions in individuals who have not had de-
pression before.2-4 This is not the type of depression we
often see at psychiatric inpatient or outpatient clinics,
where the overwhelmingmajority of patients consists of
those with 1 or more previous episodes. Several studies
have reported that only those with a history of depres-
sion and/or onset of depression before theMI—the non-
cardiotoxic subtype of post-MI depression—respond to
antidepressivemedication.5,6 A second distinction in dis-
tress that appears to be more relevant than the one be-
tween anxiety and depression is between somatic and cog-
nitive symptoms of distress. Previous studies reported that
only the somatic-affective symptoms of post-MI depres-
sion, such as sleeping problems and fatigue, which are
far more dominant in patients with CAD than in psychi-
atric patients with depression,7 were associated with an
increased risk of major adverse coronary events, and not
the cognitive symptoms, such as guilt and negative self-
view.8 Third, subtypes of distress based on the persis-
tence of symptoms appear to be of interest, which is evi-
denced in observational studies9 as well as in intervention
trials, including ENRICHDandMIND-IT.10,11 These 3 dis-
tinctions in distressedCADare relevant forDSM-V as these
aspects of distress are differentially related to cardiac prog-
nosis and/or to treatment response, while anxiety and de-
pression do not differ in this respect.
Progress in the effective treatment of distress in
patients with CAD will, in our opinion, depend on dis-
tinguishing subtypes based on empirically supported
distinctions such as those described earlier and devel-
oping interventions for these specific subtypes. To sug-
gest that we are currently on the right track in diagnos-
ing and treating distress in patients with CAD is at odds
with the available data. The largest randomized con-
trolled trial in psychosomatic medicine, ENRICHD,
reported a (significant) relative decrease of only 1.7
points on the Hamilton Rating Scale for Depression
after 24 weeks12 for cognitive behavioral therapy com-
pared with usual care (mostly no treatment). Compa-
rable results have been found in placebo-controlled
antidepressant-medication randomized controlled trials
evaluating the efficacy of selective serotonin reuptake
inhibitors (sertraline hydrochloride, 0.8 point,5 and
citalopram hydrobromide, 3.3 points, after 12 weeks6)
but also a serotonin norepinephrine reuptake inhibitor
(mirtazapine, 2.4 points).13 The standardized effect
sizes of the studies are in the range of 0.1 to 0.3 while
for depression in general the standardized effect sizes of
antidepressant medication compared with placebo are
about 0.4 to 0.8. The findings of these studies are quite
homogeneous and together suggest that guideline-based
treatment for depression developed in general psychia-
try in patients with CAD results in only minor benefits,
of which 70% to 90% can be achieved by usual care or
placebo. We hope that DSM-V will describe clinically
meaningful distinctions of distress in patients with
CAD, but we doubt whether these distinctions should
follow those in general psychiatry.
Correspondence: Dr de Jonge, Department of Psychia-
try, University Medical Center Groningen, Hanzeplein
1, 9714BWGroningen, the Netherlands (peter.de.jonge
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In reply
Drs de Jonge and Ormel believe that we should have dis-
cussed the importance of first vs recurrent depression, cog-
nitive vs somatic symptoms of depression, and the persis-
tence of symptoms, all topics on which they have written
articles. Instead, we reported the data for the primary aims
of our study: to determine the relative prognostic impor-
tance of the diagnostic categories of MDD and GAD using
the best available standardized clinical interview (Struc-
tured Clinical Interview for DSM-IV) and to compare the
prognostic importance of self-reports of symptom levels with
the diagnostic categories. In doing so, we sought to expand
and attempt to replicate our previous work that suggested
that elevated depression symptoms after an MI are associ-
ated with as great a prognostic risk as the diagnosis of ma-
jor depression.1 Unlikemost previous studies, including those
cited by de Jonge and Ormel, in which patient assessments
were made during a hospital admission for an acute MI, the
current study sample was patients with CAD whose most
recent admission had been at least 2months earlier.We found
that almost all of the risk associated with elevated depres-
sion and anxiety symptoms in these patients was accounted
for by those meetingDSM-IV criteria and that the risks as-
sociated with MDD and GADwere equivalent. We feel that
this is an important addition to the literature on heart dis-
ease and depression because it eliminated the noise created
by short-term reactions to the crisis of hospitalization in
which anxiety levels are often transiently high, provided data
on the type of patient seen most often in the community, and
is clinically useful because of the careful application of ac-
cepted psychiatric diagnostic criteria.
We have discussed the distinctions mentioned by Drs de
Jonge and Ormel in articles from our previous studies. Drs
de Jonge and Ormel appear to be unaware of these results,
which differ from their own. In 1996, we reported data from
a study of 222 post-MI patients who were assessed during
hospitalization using a modified version of the Diagnostic
Interview Schedule and observed up to 18 months for car-
diac events.2 We found that depression during hospitaliza-
tion predicted cardiac events and that the risk was greater
in those with a recurrent depression than in those with a
first depression. This is the opposite of what was reported
by Drs de Jonge and Ormel. Beyond this omission, there are
problems with the other literature they chose to substanti-
ate their view. They cite the 1992 Freedland et al article3
concerning differences between first and recurrent depres-
sions (based on the Diagnostic Interview Schedule) as evi-
dence that it is only first depressions that are “cardio-
toxic.” However, that article does not provide any data on
cardiac events for the 39 patients included and, in fact, says
that it would be interesting to look at this issue in a larger
study with longitudinal follow-up. The second article they
cite4measured past depressionwith one yes/no question about
ever having 2 weeks of depressed mood. Current depres-
sion was based on the self-report Beck Depression Inven-
tory, not a diagnostic interview. In sum, there is relatively
little evidence to support the idea that it is only first epi-
sodes of MDD following an MI that are cardiotoxic.
We have also discussed the issue of cognitive vs somatic
symptom reports in an earlier study.5 In an expanded post-MI
sample of 896 we found that cognitive and somatic symp-
tom scores based on the Beck Depression Inventory were
highly correlated (0.57). However, again our results dif-
fered from those described by de Jonge and Ormel.We found
that both cognitive and somatic symptoms were signifi-
cantly related to increased cardiac events over 5 years even
after statistical adjustment for age, sex, educational level,
daily smoking, previous MI, thrombolytic treatment for the
index MI, Q-wave MI, Killip class greater than 1, revascu-
larization at index hospitalization, left ventricular ejection
fraction, prescription of hypoglycemic agents (diabetesmelli-
tus), and β-blockers.
While we agree that one way of making greater progress
in psychiatric treatment for patients with CAD may “de-
pend on distinguishing subtypes based on empirically sup-
ported distinctions,” it may also depend on not making un-
necessary distinctions. We also differ in the way we define
empirical support. The limited existing literature con-
cerned with “subtypes” of depression in patients with CAD
is highly heterogeneous in terms of sample size and char-
acteristics, measures used, and approaches to covariate con-
trol. Additional carefully done and reported research is needed
to inform both diagnosis and treatment.
Finally, we would also like to correct the misperception
that “for depression in general the standardized effect sizes
of antidepressant medication compared with placebo are
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about 0.4 to 0.8,” while those for treating depression in car-
diac patients aremuch lower. Recent evidence based on Food
and Drug Administration files indicates that selective pub-
lication and reporting by pharmaceutical companies has in-
flated this evidence.6 The best estimate for the impact of an-
tidepressants compared with placebo is about 0.3, similar
to what was observed in the overall samples for both
CREATE7 and SADHART.8
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